基本信息
views: 5
![](https://originalfileserver.aminer.cn/sys/aminer/icon/show-trajectory.png)
Bio
His primary areas of study are Internal medicine, Cardiology, Surgery, Myocardial infarction and Endocrinology. His Internal medicine study frequently draws connections to other fields, such as Gastroenterology. His Cardiology study which covers Hazard ratio that intersects with Rivaroxaban.
His Myocardial infarction study integrates concerns from other disciplines, such as Candesartan and Placebo. His Stroke study combines topics from a wide range of disciplines, such as Anesthesia, Dabigatran, Atrial fibrillation, Warfarin and Apixaban. In his research, Vitamin K antagonist is intimately related to Edoxaban, which falls under the overarching field of Apixaban.
His Myocardial infarction study integrates concerns from other disciplines, such as Candesartan and Placebo. His Stroke study combines topics from a wide range of disciplines, such as Anesthesia, Dabigatran, Atrial fibrillation, Warfarin and Apixaban. In his research, Vitamin K antagonist is intimately related to Edoxaban, which falls under the overarching field of Apixaban.
Research Interests
Papers共 465 篇Author StatisticsCo-AuthorSimilar Experts
By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
European heart journal. Cardiovascular pharmacotherapy (2024)
EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPYno. 1 (2024): 5-6
EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPYno. 2 (2024): 87-88
Journal of the American College of Cardiology (2024)
Journal of the American Heart Associationno. 6 (2024): e032516-e032516
JACC: Heart Failure (2024)
Journal of the American College of Cardiologyno. 22 (2024): 2163-2174
GIORNALE ITALIANO DI CARDIOLOGIAno. 2 (2024): E1-E112
Cited0Views0Bibtex
0
0
EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPYno. 2 (2024): 95-97
Load More
Author Statistics
#Papers: 458
#Citation: 60602
H-Index: 71
G-Index: 71
Sociability: 8
Diversity: 3
Activity: 67
Co-Author
Co-Institution
D-Core
- 合作者
- 学生
- 导师
Data Disclaimer
The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn